USL311 is a potent, selective, orally bioavailable CXCR4 antagonist, with potential antineoplastic activity. USL311 binds to CXCR4, prevente the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, decreases proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.
Physicochemical Properties
M.Wt
422.577
Formula
C24H34N6O
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Month
Shipping
Solubility
Chemical Name/SMILES
References
1. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1
